stoxline Quote Chart Rank Option Currency Glossary
  
Aditxt, Inc. (ADTX)
1.4  0.02 (1.45%)    06-17 16:00
Open: 1.39
High: 1.42
Volume: 51,674
  
Pre. Close: 1.38
Low: 1.38
Market Cap: 3(M)
Technical analysis
2025-06-17 4:41:23 PM
Short term     
Mid term     
Targets 6-month :  1.93 1-year :  2.16
Resists First :  1.65 Second :  1.85
Pivot price 1.48
Supports First :  1.34 Second :  1.11
MAs MA(5) :  1.41 MA(20) :  1.55
MA(100) :  9.22 MA(250) :  3026.8
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  11.4 D(3) :  14.8
RSI RSI(14): 33.1
52-week High :  27200 Low :  1.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADTX ] has closed above bottom band by 25.9%. Bollinger Bands are 96.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 169 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.44
Low: 1.36 - 1.37 1.37 - 1.38
Close: 1.39 - 1.4 1.4 - 1.41
Company Description

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Headline News

Mon, 09 Jun 2025
Aditxt Strengthens Board with Women's Health Pioneer: Evofem CEO Brings 30-Year Industry Expertise - Stock Titan

Thu, 05 Jun 2025
Healthcare Innovation Leaders From Evofem, Adimune, and Pearsanta Preview New Developments at Aditxt Update - Stock Titan

Fri, 02 May 2025
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Business Wire

Thu, 10 Apr 2025
Why Aditxt Inc. (ADTX) Went Down On Thursday? - Yahoo Finance

Wed, 09 Apr 2025
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements - Business Wire

Wed, 02 Apr 2025
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 2.12e+006 (%)
Held by Institutions 0 (%)
Shares Short 239 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.14e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -550 %
Return on Assets (ttm) 895.3 %
Return on Equity (ttm) -46.4 %
Qtrly Rev. Growth 55320 %
Gross Profit (p.s.) -74.22
Sales Per Share -153.67
EBITDA (p.s.) -381271
Qtrly Earnings Growth -26 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.13
Stock Dividends
Dividend 0
Forward Dividend 45430
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android